Long-term data from the IMAGE 1 follow-up study was presented by Professor Angus Dalgleish at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington DC, USA, 7th to 11th November 2018 demonstrating that IMM-101 can be well tolerated over an extended period of up to 46 months with no additional safety signals and that survival probability results at 24 and 36 months are similar to those seen with the nab-paclitaxel/gemcitabine combination. These promising efficacy and tolerability data demonstrate that the IMM-101/gemcitabine combination could potentially be used as a first line treatment for advanced pancreatic cancer patients unable to tolerate more aggressive regimes or as a second line/maintenance therapy for this condition.

Full Title: IMAGE 1 (Immune Modulation and Gemcitabine Evaluation), A Randomised, Open-label Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer (including results from the long-term follow-up Sub-study).

Authors: Angus G Dalgleish and the IMAGE1 Trial Investigators

View Poster